Products of Bone Collagen Metabolism

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 391-405

  Risteli, Juha ^a   Risteli, Leila ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847703925     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50024-8     Document Type: Chapter

References (96)

1. Risteli J., Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J. Hepatol. 1995, (Suppl. 22):77-81.
2. Risteli J., Risteli L. Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Scand. J. Clin. Lab. Invest. 1997, (Suppl. 227):107-113.
3. Risteli L., Risteli J. Extracellular matrix metabolites in body fluids. Connective Tissue and its Heritable Disorders: Molecular, Genetic and Medical Aspects 2002, 1141-1160. John Wiley & Sons, New York. 2nd edition. P.M. Royce, B. Steinmann (Eds.).
4. Scariano J.K., Walter E.A., Glew R.H., Hollis B.W., Henry A., Ocheke I., Isicei C.O. Serum levels of pyridinoline crosslinked carboxyterminal telopeptide of type 1 collagen (ICTP) and osteocalcin in rachitic children in Nigeria. Clin. Biochem. 1995, 28:541-545.
5. Oginni L.M., Sharp C.A., Badru O.S., Risteli J., Davie M.W.J., Worsfold M. Radiological and biochemical resolution of nutritional rickets with calcium. Arch. Dis. Child. 2003, 88:812-817.
6. Leskelä H.-V., Risteli J., Niskanen S., Koivunen J., Ivaska K.K., Lehenkari P. Osteoblast recruitment from stem cells does not decrease by age at late childhood. Biochem. Biophys. Res. Commun. 2003, 311:1008-1013.
7. Jukkola A., Risteli L., Melkko J., Risteli J. Procollagen synthesis and extracellular matrix deposition in MG-63 osteosarcoma cells. J. Bone. Miner. Res. 1993, 8:651-657.
8. Mechanic G.L., Katz E.P., Henmi M., Noyes C., Yamauchi M. Locus of a histidine-based, stable trifunctional, helix to helix collagen cross-link: stereospecific collagen structure of type 1 skin fibrils. Biochemistry 1987, 26:3500-3509.
9. Eriksen H., Sharp C.A., Robins S.P., Sassi M.-L., Risteli L., Risteli J. Differently cross-linked and uncross-linked carboxy-terminal telopeptides of type 1 collagen in human mineralised bone. Bone 2004, 34:720-727.
10. Prockop D.J., Kivirikko K.I., Tuderman L., Guzman N.A. The biosynthesis of collagen and its disorders. N. Engl. J. Med. 1979, 301:13-23.
11. Prockop D.J., Kivirikko K.I., Tuderman L., Guzman N.A. The biosynthesis of collagen and its disorders. N. Engl. J. Med. 1979, 301:77-85.
12. Kessler E., Takahara K., Biniaminov L., Brusel M., Greenspan D.S. Bone morphogenetic protein-1: the type 1 procollagen C-proteinase. Science 1996, 271:360-362.
13. 2-terminal propeptides of fibrillar collagens: highly conserved domains with poorly understood functions. Matrix Biol. 2002, 21:217-226.
14. Fleischmajer R., Perlish J.S., Timpl R. Collagen fibrillogenesis in human skin. Ann. N.Y. Acad. Sci. 1985, 460:246-257.
15. Byers P.H., Cola W.G. Osteogenesis imperfecta. Connective Tissue and its Heritable Disorders 2002, 385-430. Wiley-Liss, New York. 2nd edition. P.M. Royce, B. Steinmann (Eds.).
16. Bailey A.J., Sims T.J., Knott L. Phenotypic expression of osteoblast collagen in osteoarthritic bone: production of type 1 homotrimer. Int. J. Biochem. Cell Biol. 2002, 34:176-182.
17. Mann V., Hobson E.E., Stewart T.L., Grant S.F., Robins S.P., Aspden R.M., Ralston S.H. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J. Clin. Invest. 2001, 107:899-907.
18. Clark C.C. The distributional initial characterization of oligosaccharide units on the COOH-terminal propeptide extensions of the pro-?1 and pro-?2 chains of type 1 procollagen. J. Biol. Chem. 1979, 254:10798-10802.
19. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type 1 procollagen. Clin. Chem. 1990, 36:1328-1332.
20. Pedersen B.J., Bonde M. Purification of human procollagen type 1 carboxyl-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide. Clin. Chem. 1994, 40:811-816.
21. Taubman M.B., Goldberg B., Sherr C.J. Radioimmunoassay for human procollagen. Science 1974, 186:1115-1117.
22. 2-terminal propeptide of the ?1 chain of type 1 collagen. J. Biol. Chem. 1987, 37:13457-13463.
23. Melkko J., Kauppila S., Risteli L., Niemi S., Haukipuro K., Jukkola A., Risteli J. Immunoassay for intact aminoterminal propeptide of human type 1 procollagen. Clin. Chem. 1996, 42:947-954.
24. Kauppila S., Jukkola A., Melkko J., Risteli L., Turpeenniemi-Hujanen T., Vuorinen K., Risteli J. Aminoterminal propeptide of ?1-homotrimer variant of human type I collagen (hotPINP) in malignant pleural effusion. Anticancer Res. 2001, 21:2293-2296.
25. Lee S.J., Evers S., Roeder D., Parlow A.F., Risteli J., Risteli L., Lee Y.C., Feizi T., Langen H., Nussenzweig M.C. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 2002, 295:1898-1901.
26. Smedsrød B., Pertoft H., Gustafsson S., Laurent T.C. Scavenger functions of the liver endothelial cells. Biochem. J. 1990, 266:313-327.
27. Smedsrød B., Melkko J., Risteli L., Risteli J. Circulating C-terminal propeptide of type 1 procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 1990, 271:345-350.
28. 2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J. Exp. Med. 1994, 179:405-412.
29. Kivirikko K.I. Urinary excretion of hydroxyproline in health and disease. Int. Rev. Conn. Tissue Res. 1970, 5:93-163.
30. Lamandé S.R., Bateman J.F. The type I collagen pro?1(I) COOH-terminal propeptide N-linked oligosaccharide. Functional analysis by site-directed mutagenesis. J. Biol. Chem. 1995, 270:17858-17865.
31. Toivonen J., Tähtelä R., Laitinen K., Risteli J., Välimäki M.J. Markers of bone turnover in patients with differentiated thyroid cancer on and off thyroxine suppressive therapy. Eur. J. Endocrinol. 1998, 138:667-673.
32. Sorva A., Tähtelä R., Risteli J., Risteli L., Laitinen K., Juntunen-Backman K., Sorva R. Familial high serum concentrations of the carboxyl-terminal propeptide of type I procollagen. Clin. Chem. 1994, 40:1591-1593.
33. Puistola U., Risteli L., Kauppila A., Knip M., Risteli J. Markers of type I and type III collagen synthesis in serum as indicators of tissue growth during pregnancy. J. Clin. Endocrinol. Metab. 1993, 77:178-182.
34. Sorva A., Sorva R., Risteli J., Risteli L., Autio P. Familial high serum PICP: high even in skin interstitial fluid, suppressible by topical corticosteroid treatment. Clin. Chim. Acta 2001, 314:153-157.
35. Haukipuro K., Melkko J., Risteli L., Kairaluoma M.I., Risteli J. Synthesis of type I collagen in healing wounds in humans. Ann. Surg. 1991, 213:75-80.
36. Oikarinen A., Autio P., Kiistala U., Risteli L., Risteli J. A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical glucocorticoid treatment. J. Invest. Dermatol. 1992, 98:220-225.
37. Jensen L.T., Olesen H.P., Risteli J., Lorenzen I. External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolism in lymph. Lab. Anim. Sci. 1990, 40:620-624.
38. Eriksen E.F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation to bone histomorphometry. J. Bone Miner. Res. 1993, 8:127-132.
39. Charles P., Mosekilde L., Risteli L., Risteli J., Eriksen E.F. Assessment of bone remodelling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner. 1994, 24:81-94.
40. Price K.M., Silman R., Armstrong P., Grudzinskas J.G. Development of a radioimmunoassay for fetal antigen 2. Clin. Chim. Acta 1994, 224:95-102.
41. Ørum O., Hansen M., Jensen C.H., Sørensen H.A., Jensen L.B., Hørslev-Petersen K., Teisner B. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.
42. Suvanto-Luukkonen E., Risteli L., Sundström H., Penttinen J., Kauppila A., Risteli J. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin. Chim. Acta 1997, 266:105-116.
43. Tähtelä R., Turpeinen M., Sorva R., Karonen S.-L. The amino-terminal propeptide of type I procollagen: Evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin. Biochem. 1997, 30:35-40.
44. Sharp C.A., Davie M.W.J., Worsfold M., Risteli L., Risteli J. Discrepant blood concentrations of type I procollagen propeptides in active Paget disease of bone. Clin. Chem. 1996, 42:1121-1122.
45. Sharp C.A., Risteli J., Risteli L., Davie M.W.J. Type I procollagen propeptide ratio (PICP/PINP) responds rapidly to pamidronate in Paget's disease of bone. J. Bone Min. Res. 1997, 12(Suppl 1):S269.
46. Jukkola A., Tähtelä R., Thölix E., Vuorinen K., Blanco G., Risteli L., Risteli J. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res. 1997, 57:5517-5520.
47. Simojoki M., Santala M., Risteli J., Kauppila A. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer. Gynecol. Oncol. 2003, 88:358-362.
48. Rasmussen H.B., Teisner B., Andersen J.A., Brandrup F., Purkis T., Leigh I. Immunohistochemical studies on the localization of fetal antigen 2 (FA 2), laminin and type IV collagen in basal cell carcinoma. J. Cutaneous Pathol. 1991, 18:215-219.
49. Kauppila S., Bode M., Stenbäck F., Risteli L., Risteli J. Cross-linked telopeptides of type I and III collagens in malignant ovarian tumors in vivo. Brit. J. Cancer 1999, 81:654-661.
50. Ricard-Blum S., Esterre P., Grimaud J.A. Collagen cross-linking by pyridinoline occurs in non-reversible skin fibrosis. Cell. Mol. Biol. 1993, 39:723-727.
51. Ricard-Blum S., Bresson-Hadni S., Guerret S., Grenard P., Volle P.-J., Risteli L., Grimaud J.A. Mechanism of collagen network stabilization in human irreversible granulomatous liver fibrosis. Gastroenterology 1996, 111:172-182.
52. Pornprasertsuk S., Duarte W.R., Mochida Y., Yamauchi M. Lysyl hydroxylase-2b directs collagen cross-linking pathways in MC3T3-E1 cells. J. Bone Miner. Res. 2004, 19:1349-1355.
53. Bailey A.J., Wotton S.F., Sims T.J., Thompson P.W. Biochemical changes in the collagen of human osteoporotic bone matrix. Connect. Tissue Res. 1993, 29:119-132.
54. Oxlund H., Mosekilde L., Øxtoft G. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and and osteoporosis. Bone 1996, 19:479-484.
55. Hanson D.A., Eyre D.R. Molecular site specificity of pyridinoline and pyrrole cross-linking in type I collagen in human bone. J. Biol. Chem. 1996, 271:26508-26516.
56. Brady J.D., Robins S.P. Structural characterization of pyrrolic cross-links in collagen using a biotinylated Ehrlich's reagent. J. Biol. Chem. 2001, 276:18812-18818.
57. Fledelius C., Johnsen A.H., Cloos P.A.C., Bonde M., Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a ?-isomerized Asp-Gly sequence within the C-terminal telopeptide (?1) region. J. Biol. Chem. 1997, 272:9755-9763.
58. Kenyon K., Contente S., Trackman P.C., Tang J., Kagan H.M., Friedman R.M. Lysyl oxidase and rrg messenger RNA?. Science 1991, 253:802.
59. Peyrol S., Raccurt M., Gerard F., Gleyzal C., Grimaud J.A., Sommer P. Lysyl oxidase gene expression in the stromal reactions to in situ and invasive ductal breast carcinoma. Am. J. Pathol. 1997, 150:497-507.
60. Sell D.R., Monnier V.M. Structure elucidation of a senescence cross-link from human extracellular matrix. J. Biol. Chem. 1989, 264:21597-21602.
61. Brady J.D., Ju J., Robins S.P. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation. Clin. Science 1999, 96:209-215.
62. Lowenson J., Clarke S. Does the chemical instability of aspartyl and asparaginyl residues in proteins contribute to erythrocyte aging. Blood Cells 1988, 14:103-117.
63. Garnero P., Fledelius C., Gineyts E., Serre C.-M., Vignot E., Delmas P.D. Decreased ?-isomerization of the C-terminal telopeptide of type I collagen ?1 chain in Paget's disease of bone. J. Bone Miner. Res. 1997, 12:1407-1415.
64. Helfman P.M., Bada J.L. Aspartic acid racemisation in dentine as a measure of ageing. Nature 1976, 262:279-281.
65. Everts V., van der Zee E., Creemers L., Beertsen W. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem. J. 1996, 28:229-245.
66. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., Foged N.T., Delmas P.D., Delaissé J.-M. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 1998, 273:32347-32352.
67. Clemens J.D., Herrick M.V., Singer F.R., Eyre D.R. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 1997, 43:2058-2063.
68. Hanson D.A., Weis M.A.E., Bollen A.-M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 1992, 7:1251-1258.
69. Blumsohn A.C., Naylor K., Eastell R. Effect of light and ?-irridiation on pyridinolines and telopeptide of type I collagen in urine. Clin. Chem. 1995, 41:1195-1197.
70. Hartmann D., Trinchet J.C., Ricard-Blum S., Beaugrand M., Callard P., Ville G. Radioimmunoassay of type I collagen that mainly detects degradation products in serum: application to patients with liver diseases. Clin. Chem. 1990, 36:421-426.
71. Ju J., Leigh S., Byrne M., van der Rest M., Liu V., Krane S. A new marker for measuring bone resorption using an ELISA for a 14 amino acid peptide (residues 620-633) derived from the collagen ?1(I) chain. J. Bone Miner. Res. 1997, 12(Suppl):S178.
72. Ju H.-S.J., Maskrey J., Krane S., Riggs B.L., Allen G. An immunoassay for measuring helical peptide/?1(I) 620-633 derived from type I collagen ?1 chain. Bone 1998, 23(Suppl):S629.
73. Garnero P., Delmas P.D. An immunoassay for type I collagen ?1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone 2003, 32:20-26.
74. Furthmayr H. Immunization procedures, isolation by affinity chromatography, and serological and immunochemical characterization of collagen specific antibodies. Immunochemistry of the Extracellular Matrix Volume I Methods 1982, 143-178. CRC Press, Boca Raton, FL. H. Furthmayr (Ed.).
75. Kitinsert Metra Helical Peptide EIA kit. Quidel, 0760A (5/01) Catalog number 8022 2001, 1-3. read August 17, 2004. http://www.quidel.com.
76. Taxel P., Fall P.M., Prestwood K.M., Dulipsingh L., Ohannessian C., Raisz L.G. Changes in urinary excretion of helical peptide during therapy for osteoporosis in older adults. Clin. Chem. 2004, 50:747-750.
77. Robins S.P. Turnover and cross-linking of collagen. Collagen in Health and Disease 1982, 160-178. Churchill Livingstone, Edinburgh. J.B. Weiss, M.I.V. Jayson (Eds.).
78. Bettica P., Taylor A.K., Talbot J., Moro L., Talamini R., Baylink D.J. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 1996, 81:542-546.
79. Leigh S.D., Ju H.S., Lundgard R., Daniloff G.Y., Liu V. Development of an immunoassay for urinary galactosylhydroxylysine. J. Immunol. Methods 1998, 220:169-178.
80. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin. Chem. 1993, 39:635-640.
81. Sassi M.-L., Eriksen H., Risteli L., Niemi S., Mansell J., Gowen M., Risteli J. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone 2000, 26:367-373.
82. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine. Clin. Chem. 1994, 40:2022-2025.
83. Bonde M., Gamero P., Fledelius C., Qvist P., Delmas P.D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J. Bone Miner. Res. 1997, 12:1028-1034.
84. Rosenqvist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P., Christiansen C. Serum CrossLaps One Step ELISA First application of monoclonal antibodies for measurement in serum of bone-related degradation products of type I collagen. Clin. Chem. 1998, 44:2281-2289.
85. Gineyts E., Cloos P.A.C., Borel O., Grimaud L., Delmas P.D., Gamero P. Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochem. J. 2000, 345:481-485.
86. Väänänen H.K., Zhao H., Mulari M., Halleen J.M. The cell biology of osteoclast function. J. Cell Sci. 2000, 113:377-381.
87. Atley L.M., Mort J.S., Lalumiere M., Eyre D.R. Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone 2000, 26:241-247.
88. Sassi M.-L., Man S., Hakala M., Luukkainen R., Risteli J. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis. Clin. Chem. Lab. Med. 2003, 41:1038-1044.
89. Nishi Y., Atley L., Wyre D.E., Edelson J.G., Superti-Furga A., Yasuda T., Desnick R.J., Gelb B.D. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J. Bone Min. Res. 1999, 14:1902-1908.
90. Foged N.T., Delaissé J.-M., Hou P., Lou H., Sato T., Winding B., Bonde M. Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay. J. Bone Miner. Res. 1996, 11:226-237.
91. Apone S., Lee M.Y., Eyre D.R. Osteoclasts generate cross-linked collagen N-telopeptides (Ntx) but not free pyridinolines when cultured on human bone. Bone 1997, 21:129-136.
92. Parikka V., Lehenkari P., Sassi M.-L., Halleen J., Risteli J., Härkönen P., Väänänen H.K. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology 2001, 142:5371-5378.
93. Gamero P., Ferreras M., Karsdal K.A., Nicamhlaoibh R., Risteli J., Borel O., Qvist P., Delmas P.D., Foged N.T., Delaissé J.M. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J. Bone. Miner. Res. 2003, 18:859-867.
94. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J. Bone Miner. Res. 1995, 10:641-649.
95. Ruckidge G.J., Riddoch G.I., Williams L.M., Robins S.P. Autoradiographic studies of the renal clearance of circulating Type I collagen fragments in the rat. Collagen Rel. Res. 1988, 8:339-348.
96. Colwell A., Eastell R. The renal clearance of free and conjugated pyridinium cross-links of collagen. J. Bone Miner. Res. 1996, 11:1976-1980.